Table 4 Subgroup analyses for the relationship between high expression of lncFTX and the survival of patients with cancer
From: Prognostic significance of long non-coding RNA five prime to XIST in various cancers
Subgroup | Studies | HR and 95% CI | Effects model | Heterogeneity (p; I2) |
|---|---|---|---|---|
Cases | 8 | 1.83 (1.20–2.81) | Random | 0.001; 72.2% |
≥ 100 | 5 | 1.63 (0.92–2.89) | Random | 0.000; 81.8% |
< 100 | 3 | 2.50 (1.57–3.99) | Fixed | 0.906; 0.0% |
Cancer types | 8 | 1.83 (1.20–2.81) | Random | 0.001; 72.2% |
Glioma | 2 | 3.99 (1.98–8.06) | Fixed | 0.263; 20.1% |
Osteosarcoma | 2 | 2.48 (1.46–4.20) | Fixed | 0.661; 0.0% |
Colorectal cancer | 2 | 1.76 (1.25–2.46) | Fixed | 0.734; 0.0% |
Others | 2 | 0.90 (0.31–2.62) | Random | 0.006; 86.7% |